ASX - By Stock
|
MSB |
Re:
Pick Today's Price Range Low-High... Just for Fun
|
|
Martin37
|
695 |
230K |
22 |
14/05/24 |
14/05/24 |
ASX - By Stock
|
695
|
230K
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Pick Today's Price Range Low-High... Just for Fun
|
|
Martin37
|
695 |
230K |
35 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
695
|
230K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
Pick Today's Price Range Low-High... Just for Fun
|
|
Martin37
|
695 |
230K |
11 |
13/05/24 |
13/05/24 |
ASX - By Stock
|
695
|
230K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
No Need to Stress! BUY like GOLD, HOLD like GOLD
|
|
Martin37
|
8 |
2.4K |
25 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
8
|
2.4K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Martin37
|
3.4K |
1.2M |
39 |
09/07/23 |
09/07/23 |
ASX - By Stock
|
3.4K
|
1.2M
|
39
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Reports Q3 Financial Results and Operational Highlights
|
|
Martin37
|
362 |
114K |
62 |
27/05/23 |
27/05/23 |
ASX - By Stock
|
362
|
114K
|
62
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Reports Q3 Financial Results and Operational Highlights
|
|
Martin37
|
362 |
114K |
21 |
27/05/23 |
27/05/23 |
ASX - By Stock
|
362
|
114K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
RWE for 2nd MSB COVID-19 ARDS P3 Trial
|
|
Martin37
|
905 |
290K |
32 |
05/05/23 |
05/05/23 |
ASX - By Stock
|
905
|
290K
|
32
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Martin37
|
207 |
61K |
31 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
207
|
61K
|
31
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Martin37
|
207 |
61K |
25 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
207
|
61K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.8M |
25 |
18/04/23 |
18/04/23 |
ASX - By Stock
|
17K
|
6.8M
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.8M |
32 |
18/04/23 |
18/04/23 |
ASX - By Stock
|
17K
|
6.8M
|
32
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.8M |
29 |
07/04/23 |
07/04/23 |
ASX - By Stock
|
17K
|
6.8M
|
29
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.8M |
24 |
07/04/23 |
07/04/23 |
ASX - By Stock
|
17K
|
6.8M
|
24
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
|
|
Martin37
|
1.0K |
393K |
38 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
1.0K
|
393K
|
38
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MESOBLAST CURES SR-aGVHD IN CHILDREN
|
|
Martin37
|
81 |
37K |
40 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
81
|
37K
|
40
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MESOBLAST CURES SR-aGVHD IN CHILDREN
|
|
Martin37
|
81 |
37K |
30 |
23/02/23 |
23/02/23 |
ASX - By Stock
|
81
|
37K
|
30
|
|
ASX - By Stock
|
MSB Biotech |
Re:
Why are PNV holders frequenting MSB?
|
|
Martin37
|
13 |
5.2K |
36 |
10/08/22 |
10/08/22 |
ASX - By Stock
|
13
|
5.2K
|
36
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB 2022 - The road to commercialisation
|
|
Martin37
|
1.5K |
507K |
45 |
09/08/22 |
09/08/22 |
ASX - By Stock
|
1.5K
|
507K
|
45
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB 2022 - The road to commercialisation
|
|
Martin37
|
1.5K |
507K |
32 |
14/07/22 |
14/07/22 |
ASX - By Stock
|
1.5K
|
507K
|
32
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MSB 2022 - The road to commercialisation
|
|
Martin37
|
1.5K |
507K |
40 |
14/07/22 |
14/07/22 |
ASX - By Stock
|
1.5K
|
507K
|
40
|
|
ASX - By Stock
|
MSB |
Re:
How low can we go?
|
|
Martin37
|
184 |
39K |
43 |
07/07/22 |
07/07/22 |
ASX - By Stock
|
184
|
39K
|
43
|
|
ASX - By Stock
|
MSB |
Re:
MSB All-time low Party Thread
|
|
Martin37
|
396 |
108K |
15 |
02/07/22 |
02/07/22 |
ASX - By Stock
|
396
|
108K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
MSB All-time low Party Thread
|
|
Martin37
|
396 |
108K |
18 |
02/07/22 |
02/07/22 |
ASX - By Stock
|
396
|
108K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
MSB All-time low Party Thread
|
|
Martin37
|
396 |
108K |
76 |
01/07/22 |
01/07/22 |
ASX - By Stock
|
396
|
108K
|
76
|
|
ASX - By Stock
|
MSB |
Re:
Chronic Lower Back Pain - the sleeping giant.
|
|
Martin37
|
484 |
147K |
18 |
18/06/22 |
18/06/22 |
ASX - By Stock
|
484
|
147K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast hit with 4th shareholder class action
|
|
Martin37
|
257 |
78K |
23 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
257
|
78K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast hit with 4th shareholder class action
|
|
Martin37
|
257 |
78K |
4 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
257
|
78K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast hit with 4th shareholder class action
|
|
Martin37
|
257 |
78K |
6 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
257
|
78K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Chronic Lower Back Pain - the sleeping giant.
|
|
Martin37
|
484 |
147K |
3 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
484
|
147K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Chronic Lower Back Pain - the sleeping giant.
|
|
Martin37
|
484 |
147K |
20 |
17/06/22 |
17/06/22 |
ASX - By Stock
|
484
|
147K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast hit with 4th shareholder class action
|
|
Martin37
|
257 |
78K |
11 |
16/06/22 |
16/06/22 |
ASX - By Stock
|
257
|
78K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast hit with 4th shareholder class action
|
|
Martin37
|
257 |
78K |
11 |
16/06/22 |
16/06/22 |
ASX - By Stock
|
257
|
78K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast hit with 4th shareholder class action
|
|
Martin37
|
257 |
78K |
10 |
16/06/22 |
16/06/22 |
ASX - By Stock
|
257
|
78K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
50 cents
|
|
Martin37
|
101 |
28K |
6 |
02/06/22 |
02/06/22 |
ASX - By Stock
|
101
|
28K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Third Quarter Results Presentation
|
|
Martin37
|
15 |
7.1K |
9 |
01/06/22 |
01/06/22 |
ASX - By Stock
|
15
|
7.1K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Ann: MSB Q3 Financial Results and Operational Highlights
|
|
Martin37
|
177 |
60K |
23 |
01/06/22 |
01/06/22 |
ASX - By Stock
|
177
|
60K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.8M |
4 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
17K
|
6.8M
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients
|
|
Martin37
|
70 |
25K |
25 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
70
|
25K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L Survival Outcomes in COVID-19 ARDS Patients
|
|
Martin37
|
70 |
25K |
18 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
70
|
25K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
Martin37
|
1.1K |
350K |
1 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
1.1K
|
350K
|
1
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
Martin37
|
1.1K |
350K |
6 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
1.1K
|
350K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
Martin37
|
1.1K |
350K |
18 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
1.1K
|
350K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
Martin37
|
1.1K |
350K |
5 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
1.1K
|
350K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
MSB $1 Party
|
|
Martin37
|
1.1K |
350K |
8 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
1.1K
|
350K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.8M |
22 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
17K
|
6.8M
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.8M |
34 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
17K
|
6.8M
|
34
|
|
ASX - By Stock
|
MSB |
Re:
Crohn’s Disease
|
|
Martin37
|
150 |
55K |
23 |
20/05/22 |
20/05/22 |
ASX - By Stock
|
150
|
55K
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Crohn’s Disease
|
|
Martin37
|
150 |
55K |
9 |
20/05/22 |
20/05/22 |
ASX - By Stock
|
150
|
55K
|
9
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Martin37
|
17K |
6.8M |
23 |
20/05/22 |
20/05/22 |
ASX - By Stock
|
17K
|
6.8M
|
23
|
|